Volume 142, Issue 2, Pages (August 2016)

Slides:

Advertisements

Similar presentations

ABO-incompatible kidney transplantation Kota Takahashi, Kazuhide Saito Transplantation Reviews Volume 27, Issue 1, Pages 1-8 (January 2013) DOI: /j.trre

Advertisements

Small-Cell Carcinoma in Association With a Mature Cystic Teratoma of the Ovary: A Case Report With Literature Review Karina E. Hew, Kimberley Studeman,

Nicoletta Colombo, Martin Gore

Volume 144, Issue 1, Pages (January 2017)

Volume 64, Pages e1-e3 (January 2017)

Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade.

Volume 148, Issue 1, Pages (January 2018)

Volume 150, Issue 1, Pages (July 2018)

Volume 148, Issue 1, Pages (January 2018)

Rajmohan Murali, Rachel N. Grisham, Robert A. Soslow

Are patients willing to travel for better ovarian cancer care?

Volume 148, Issue 1, Pages (January 2018)

L. C. Parsons, S. A. Sullivan, C. Garcia, T. Castellano, V. L

Volume 148, Issue 1, Pages (January 2018)

Volume 146, Issue 3, Pages (September 2017)

Volume 150, Issue 3, Pages (September 2018)

Volume 149, Issue 2, Pages (May 2018)

Volume 145, Issue 2, Pages (May 2017)

Vulvar intraepithelial neoplasia: Risk factors for recurrence

Corrigendum to “MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer” [Gynecologic Oncology 110: 13–21, 2008] Douglas.

Volume 144, Issue 2, Pages (February 2017)

Volume 147, Issue 1, Pages 3-10 (October 2017)

Joachim Pfannschmidt, MD, Hans Hoffmann, MD, Hendrick Dienemann, MD

The efficacy of mTORC1/2 inhibition on ovarian cancer stem cells

Volume 152, Issue 1, Pages (January 2019)

M. Ulm, D. Lee, A.R. Mabe, M.P. Lowe, S. Kumar, T. Tillmanns

Wilberto Nieves-Neira, J. Julie Kim, Daniela Matei

Volume 148, Issue 1, Pages (January 2018)

Volume 136, Issue 2, Pages (February 2015)

Cancer Moonshot: Patents for Patients

The development and use of vascular targeted therapy in ovarian cancer

National trends in management of stage IIIC1 and IIIC2 uterine cancer: Chemotherapy and radiotherapy in isolation and sequence J. Chino, J.R. Foote,

Volume 152, Issue 1, Pages (January 2019)

Pathologic response at interval debulking surgery following neoadjuvant chemotherapy predicts improved survival in women with ovarian cancer E.N. Prendergast,

K. Bixel, N. Denlinger, L. Marsh, A. Quick, R. Salani

Volume 152, Issue 1, Pages (January 2019)

Volume 152, Issue 1, Pages (January 2019)

Volume 143, Issue 2, Pages (November 2016)

Laparoscopic staging for stage I epithelial ovarian cancer: Analysis of the National Cancer Data Base A. Melamed, J.T. Clemmer, N.L. Keating, J.D. Wright,

Adherence to hematologic hold parameters in dose-dense chemotherapy for ovarian malignancies: A survey of the National Comprehensive Cancer Network (NCCN)

Comparing the health and economic impacts of cervical cancer screening strategies using the Cancer Risk Management Model (CRMM) C. Popadiuk, A.J. Coldman,

I. Mert, A. R. Munkarah, R. K. Hanna, J. Chhina, M. S. Carey, M

Survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum A. Ellis, M.K. Frey, L.M. Koontz, S. Shyne,

Volume 152, Issue 1, Pages (January 2019)

Volume 152, Issue 1, Pages (January 2019)

Are ovarian cancer debulking models reliable: Variance and predictability are dependent on institutional optimal debulking rates N.A. Latif, E.M. Ko,

Volume 152, Issue 1, Pages (January 2019)

Volume 147, Issue 1, Pages (October 2017)

Volume 152, Issue 1, Pages (January 2019)

Limited access safety lead-in of the MEK inhibitor trametinib in combination with GSK , an AKT inhibitor, in patients with recurrent or persistent.

Volume 152, Issue 1, Pages (January 2019)

The complex interaction of cancer surgery, complications, and patient-reported outcomes: A single score is not enough K.M. Doll, E.L. Barber, J.T. Bensen,

Annika Idahl, Andrea Hermansson, Ann Lalos Gynecologic Oncology

Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival: an NRG Oncology/Gynecologic Oncology Group study

Volume 17, Issue 2, Pages (February 1950)

Volume 147, Issue 3, Pages (December 2017)

Volume 152, Issue 1, Pages (January 2019)

Volume 130, Issue 1, Pages (July 2013)

Volume 152, Issue 1, Pages (January 2019)

Volume 151, Issue 1, Pages (October 2018)

Upregulated Wnt signaling is associated with increased survival of patients with high- grade serous ovarian cancer M. Dandapani, B.L. Seagle, R. Samuelson,

Volume 130, Issue 1, Pages (July 2013)

Erratum to “Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma” [Gynecol Oncol. 120 (2011) 11–17] Heini Lassus,

Volume 152, Issue 1, Pages (January 2019)

Volume 152, Issue 1, Pages (January 2019)

Should ovarian preservation be considered for women younger than 60 years with endometrial carcinoma? L.M. Bean, K. Taylor, K.M. Anderson, M.A. Davis,

Volume 154, Issue 1, Pages (July 2019)

Volume 115, Issue 1, Pages (October 2009)

Volume 154, Issue 1, Pages (July 2019)

Volume 154, Issue 2, Pages (August 2019)

Presentation transcript:

Volume 142, Issue 2, Pages 231-236 (August 2016) Impact of bevacizumab containing first line chemotherapy on recurrent disease in epithelial ovarian cancer: A case-control study M. Petrillo, G. Amadio, V. Salutari, I. Paris, M.G. Di Stefano, G. Ferandina, G. Scambia, A. Fagotti Gynecologic Oncology Volume 142, Issue 2, Pages 231-236 (August 2016) DOI: 10.1016/j.ygyno.2016.05.017 Copyright © 2016 Elsevier Inc. Terms and Conditions

Fig. 1 Flow-chart of our study population. Gynecologic Oncology 2016 142, 231-236DOI: (10.1016/j.ygyno.2016.05.017) Copyright © 2016 Elsevier Inc. Terms and Conditions

Fig. 2 Platinum-free interval in Cases (solid line) and Controls (dotted line). Gynecologic Oncology 2016 142, 231-236DOI: (10.1016/j.ygyno.2016.05.017) Copyright © 2016 Elsevier Inc. Terms and Conditions

Fig. 3 Time to Progression to second line chemotherapy in Cases (solid line) and Controls (dotted line). Gynecologic Oncology 2016 142, 231-236DOI: (10.1016/j.ygyno.2016.05.017) Copyright © 2016 Elsevier Inc. Terms and Conditions